Literature DB >> 15000674

Aging in individuals with the FMR1 mutation.

S Jacquemont1, F Farzin, D Hall, M Leehey, F Tassone, L Gane, L Zhang, J Grigsby, T Jardini, F Lewin, E Berry-Kravis, P J Hagerman, R J Hagerman.   

Abstract

Individuals with fragile X mental retardation 1 (FMR1) premutation (55 to 200 CGG repeats) are typically unaffected by fragile X syndrome. However, a subgroup of older males with the premutation have developed a neurological syndrome, which usually begins between 50 and 70 years and is associated with a progressive intention tremor and/or ataxia manifested by balance problems, frequent falling, and Parkinsonian symptoms, such as masked facies, intermittent resting tremor, and mild rigidity. This finding has been termed the fragile X-associated tremor/ataxia syndrome (FXTAS) and has brought focus to the aging process in individuals with the FMR1 mutation. The premutation is associated with elevated messenger RNA levels leading to the formation of intranuclear inclusions in neurons and astrocytes associated with FXTAS. This review is a summary of our experience with FXTAS in male carriers of the premutation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15000674      PMCID: PMC3249442          DOI: 10.1352/0895-8017(2004)109<154:AIIWTF>2.0.CO;2

Source DB:  PubMed          Journal:  Am J Ment Retard        ISSN: 0895-8017


  28 in total

Review 1.  Apoptosis and caspases in neurodegenerative diseases.

Authors:  Robert M Friedlander
Journal:  N Engl J Med       Date:  2003-04-03       Impact factor: 91.245

2.  Cerebellar Ataxia.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-05       Impact factor: 3.598

3.  The FMR1 CGG repeat mouse displays ubiquitin-positive intranuclear neuronal inclusions; implications for the cerebellar tremor/ataxia syndrome.

Authors:  Rob Willemsen; Marianne Hoogeveen-Westerveld; Surya Reis; Joan Holstege; Lies-Anne W F M Severijnen; Ingeborg M Nieuwenhuizen; Mariette Schrier; Leontine van Unen; Flora Tassone; Andre T Hoogeveen; Paul J Hagerman; Edwin J Mientjes; Ben A Oostra
Journal:  Hum Mol Genet       Date:  2003-05-01       Impact factor: 6.150

4.  Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat.

Authors:  A Mankodi; E Logigian; L Callahan; C McClain; R White; D Henderson; M Krym; C A Thornton
Journal:  Science       Date:  2000-09-08       Impact factor: 47.728

5.  Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease.

Authors:  M Chen; V O Ona; M Li; R J Ferrante; K B Fink; S Zhu; J Bian; L Guo; L A Farrell; S M Hersch; W Hobbs; J P Vonsattel; J H Cha; R M Friedlander
Journal:  Nat Med       Date:  2000-07       Impact factor: 53.440

6.  Tremor and ataxia in fragile X premutation carriers: blinded videotape study.

Authors:  Elizabeth Berry-Kravis; Foster Lewin; Joanne Wuu; Maureen Leehey; Randi Hagerman; Paul Hagerman; Christopher G Goetz
Journal:  Ann Neurol       Date:  2003-05       Impact factor: 10.422

7.  Reduced FMR1 mRNA translation efficiency in fragile X patients with premutations.

Authors:  Beatrice Primerano; Flora Tassone; Randi J Hagerman; Paul Hagerman; Francesco Amaldi; Claudia Bagni
Journal:  RNA       Date:  2002-12       Impact factor: 4.942

8.  Rapid antibody test for fragile X syndrome.

Authors:  R Willemsen; S Mohkamsing; B de Vries; D Devys; A van den Ouweland; J L Mandel; H Galjaard; B Oostra
Journal:  Lancet       Date:  1995-05-06       Impact factor: 79.321

Review 9.  Myotonic syndromes.

Authors:  Ami Mankodi; Charles A Thornton
Journal:  Curr Opin Neurol       Date:  2002-10       Impact factor: 5.710

10.  Amantadine hydrochloride treatment in heredodegenerative ataxias: a double blind study.

Authors:  M I Botez; T Botez-Marquard; R Elie; O L Pedraza; K Goyette; R Lalonde
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-09       Impact factor: 10.154

View more
  49 in total

Review 1.  Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder.

Authors:  Reymundo Lozano; Veronica Martinez-Cerdeno; Randi J Hagerman
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

2.  Size bias of fragile X premutation alleles in late-onset movement disorders.

Authors:  Sebastien Jacquemont; Maureen A Leehey; Randi J Hagerman; Laurel A Beckett; Paul J Hagerman
Journal:  J Med Genet       Date:  2006-05-24       Impact factor: 6.318

Review 3.  A review of fragile X premutation disorders: expanding the psychiatric perspective.

Authors:  James A Bourgeois; Sarah M Coffey; Susan M Rivera; David Hessl; Louise W Gane; Flora Tassone; Claudia Greco; Brenda Finucane; Lawrence Nelson; Elizabeth Berry-Kravis; Jim Grigsby; Paul J Hagerman; Randi J Hagerman
Journal:  J Clin Psychiatry       Date:  2009-05-05       Impact factor: 4.384

4.  Clinically significant psychiatric symptoms among male carriers of the fragile X premutation, with and without FXTAS, and the mediating influence of executive functioning.

Authors:  Jim Grigsby; Angela G Brega; Rachael E Bennett; James A Bourgeois; Andreea L Seritan; Glenn K Goodrich; Randi J Hagerman
Journal:  Clin Neuropsychol       Date:  2016-06-29       Impact factor: 3.535

Review 5.  What has been learned from mouse models of the Fragile X Premutation and Fragile X-associated tremor/ataxia syndrome?

Authors:  Molly M Foote; Milo Careaga; Robert F Berman
Journal:  Clin Neuropsychol       Date:  2016-06-29       Impact factor: 3.535

Review 6.  FMR1: a gene with three faces.

Authors:  Ben A Oostra; Rob Willemsen
Journal:  Biochim Biophys Acta       Date:  2009-02-21

7.  Eye movements reveal impaired inhibitory control in adult male fragile X premutation carriers asymptomatic for FXTAS.

Authors:  Ling M Wong; Naomi J Goodrich-Hunsaker; Yingratana McLennan; Flora Tassone; Melody Zhang; Susan M Rivera; Tony J Simon
Journal:  Neuropsychology       Date:  2014-04-28       Impact factor: 3.295

8.  Dementia in fragile X-associated tremor/ataxia syndrome (FXTAS): comparison with Alzheimer's disease.

Authors:  Andreea L Seritan; Danh V Nguyen; Sarah Tomaszewski Farias; Ladson Hinton; Jim Grigsby; James A Bourgeois; Randi J Hagerman
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2008-10-05       Impact factor: 3.568

9.  Expanded clinical phenotype of women with the FMR1 premutation.

Authors:  Sarah M Coffey; Kylee Cook; Nicole Tartaglia; Flora Tassone; Danh V Nguyen; Ruiqin Pan; Hannah E Bronsky; Jennifer Yuhas; Mariya Borodyanskaya; Jim Grigsby; Melanie Doerflinger; Paul J Hagerman; Randi J Hagerman
Journal:  Am J Med Genet A       Date:  2008-04-15       Impact factor: 2.802

10.  Argonaute2 suppresses Drosophila fragile X expression preventing neurogenesis and oogenesis defects.

Authors:  Anita S-R Pepper; Rebecca W Beerman; Balpreet Bhogal; Thomas A Jongens
Journal:  PLoS One       Date:  2009-10-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.